Despite the appeal of stopping treatment, a key insight from clinical practice is that patients' most critical question remains which therapy offers the longest period of remission, often overriding factors like treatment duration and oral-only options.
While the continuous BTK inhibitor zanubrutinib showed longer progression-free survival, this efficacy came with a significant safety trade-off. It led to a 47% rate of serious adverse events compared to 24% for the fixed-duration acalabrutinib-venetoclax combination in the indirect analysis.
Comparing trials like Sequoia (zanubrutinib) and Amplify (acalabrutinib-venetoclax) is invalid without adjusting for baseline population differences. Amplify's inclusion of an FCR chemo-arm meant its patients were inherently more fit, necessitating statistical matching for a fair comparison.
The current pace of innovation in CLL treatment means new options become available faster than long-term clinical trials can conclude. This creates a critical need for more efficient trial designs and validated intermediate endpoints that can provide reliable answers sooner.
Individual investigators cannot conduct deeper, meaningful post-hoc analyses without access to patient-level data from original clinical trials. Progress requires collaboration with pharmaceutical manufacturers who hold this data, allowing for more nuanced comparisons beyond initial publications.